Duncan McHale - Jan 19, 2022 Form 4 Insider Report for Evelo Biosciences, Inc. (EVLO)

Role
Chief Medical Officer
Signature
/s/ Daniel S. Char, Attorney-in-Fact for Duncan McHale
Stock symbol
EVLO
Transactions as of
Jan 19, 2022
Transactions value $
$0
Form type
4
Date filed
1/21/2022, 03:53 PM
Next filing
May 31, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Stock Option (Right to Buy) Award $0 +100K $0.00 100K Jan 19, 2022 Common Stock 100K $5.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options will vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of the date of grant, subject to continued employment on such dates.

Remarks:

Exhibit 24 - Power of Attorney